149 related articles for article (PubMed ID: 1648976)
1. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant.
Bowden RA; Slichter SJ; Sayers MH; Mori M; Cays MJ; Meyers JD
Blood; 1991 Jul; 78(1):246-50. PubMed ID: 1648976
[TBL] [Abstract][Full Text] [Related]
2. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors.
De Witte T; Schattenberg A; Van Dijk BA; Galama J; Olthuis H; Van der Meer JW; Kunst VA
Transplantation; 1990 Dec; 50(6):964-8. PubMed ID: 2175059
[TBL] [Abstract][Full Text] [Related]
3. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant.
Bowden RA; Slichter SJ; Sayers M; Weisdorf D; Cays M; Schoch G; Banaji M; Haake R; Welk K; Fisher L; McCullough J; Miller W
Blood; 1995 Nov; 86(9):3598-603. PubMed ID: 7579469
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation.
Verdonck LF; de Graan-Hentzen YC; Dekker AW; Mudde GC; de Gast GC
Bone Marrow Transplant; 1987 Jun; 2(1):73-8. PubMed ID: 2844337
[TBL] [Abstract][Full Text] [Related]
5. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters.
van Prooijen HC; Visser JJ; van Oostendorp WR; de Gast GC; Verdonck LF
Br J Haematol; 1994 May; 87(1):144-7. PubMed ID: 7947238
[TBL] [Abstract][Full Text] [Related]
6. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B
Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
[TBL] [Abstract][Full Text] [Related]
7. Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors.
Ljungman P; Larsson K; Kumlien G; Aschan J; Barkholt L; Gustafsson-Jernberg A; Lewensohn-Fuchs I; Ringdén O
Scand J Infect Dis; 2002; 34(5):347-50. PubMed ID: 12069017
[TBL] [Abstract][Full Text] [Related]
8. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening.
Miller WJ; McCullough J; Balfour HH; Haake RJ; Ramsay NK; Goldman A; Bowman R; Kersey J
Bone Marrow Transplant; 1991 Mar; 7(3):227-34. PubMed ID: 1647829
[TBL] [Abstract][Full Text] [Related]
9. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
Narvios AB; Lichtiger B
Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
[TBL] [Abstract][Full Text] [Related]
10. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
Winston DJ; Ho WG; Bartoni K; Champlin RE
Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus-seronegative blood components for the prevention of primary cytomegalovirus infection after marrow transplantation. Considerations for blood banks.
Bowden RA; Sayers M; Gleaves CA; Banaji M; Newton B; Meyers JD
Transfusion; 1987; 27(6):478-81. PubMed ID: 2825381
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant.
Bowden RA; Fisher LD; Rogers K; Cays M; Meyers JD
J Infect Dis; 1991 Sep; 164(3):483-7. PubMed ID: 1651360
[TBL] [Abstract][Full Text] [Related]
14. Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a U.K. dual centre experience.
Hall S; Danby R; Osman H; Peniket A; Rocha V; Craddock C; Murphy M; Chaganti S
Transfus Med; 2015 Dec; 25(6):418-23. PubMed ID: 26114211
[TBL] [Abstract][Full Text] [Related]
15. Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation.
Mackinnon S; Burnett AK; Crawford RJ; Cameron S; Leask BG; Sommerville RG
J Clin Pathol; 1988 Sep; 41(9):948-50. PubMed ID: 2848062
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM
Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
[TBL] [Abstract][Full Text] [Related]
17. Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy.
Reddy V; Hao Y; Lipton J; Meharchand J; Minden M; Mazzulli T; Chan C; Messner HA
J Clin Virol; 1999 Aug; 13(3):149-59. PubMed ID: 10443791
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study.
Boeckh M; Gooley TA; Myerson D; Cunningham T; Schoch G; Bowden RA
Blood; 1996 Nov; 88(10):4063-71. PubMed ID: 8916975
[TBL] [Abstract][Full Text] [Related]
19. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
[TBL] [Abstract][Full Text] [Related]
20. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
